MedWorm: Pharmaceuticals

Ceapro inc.: departure of mr. mark redmond, ph.d. as president & ceo of ceapro

Market Wire - Pharmaceuticals and Biotech — Fri, 04 Jul 2008 19:00:00 +0100

EDMONTON, ALBERTA (MARKET WIRE) Ceapro Inc. (TSX VENTURE: CZO) The Company regrets to inform shareholders that Mr. Mark Redmond, Ph.D has decided to step down as a Director and an Officer of the Company effective immediately. In the mean time, Mr. Gilles R. Gagnon, an independent Director of the Company will act as President & CEO during the search period for a new CEO. (Source: Market Wire - Pharmaceuticals and Biotech)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Protherics plc: protherics plc announces interest in shares

Market Wire - Pharmaceuticals and Biotech — Fri, 04 Jul 2008 16:12:00 +0100

CHESHIRE, UK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech)

Protherics plc: protherics plc announces issue of shares

Market Wire - Pharmaceuticals and Biotech — Fri, 04 Jul 2008 16:04:00 +0100

CHESHIRE, UK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech)

Southern cross strengthens board

FT.com - Drugs and Healthcare — Fri, 04 Jul 2008 14:16:00 +0100

The nursing home group appointed a former nurse to its management board in the wake of its disastrous profits warning earlier in the week (Source: FT.com - Drugs and Healthcare)

Myriad terminates phase iii alzheimer’s disease therapy

Pharmaprojects' Pharma R&D Pipeline News — Fri, 04 Jul 2008 12:48:04 +0100

US-based Myriad Genetics has announced that it has discontinued development of tarenflurbil (Flurizan)... more (Source: Pharmaprojects' Pharma R&D Pipeline News)

Novexel discontinues mrsa agent

Pharmaprojects' Pharma R&D Pipeline News — Fri, 04 Jul 2008 10:00:44 +0100

Novexel has discontinued the development of its antibacterial agent, NXL-101 due to adverse events in a Phase I trial... more (Source: Pharmaprojects' Pharma R&D Pipeline News)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Ge healthcare's omnipaque helpful as oral contrast agent, technical note reports

Pharma Industry News From Medical News Today — Fri, 04 Jul 2008 08:00:00 +0100

Low-osmolar contrast media, such as GE Healthcare's Omnipaque (Iohexol), make effective oral contrast agents for abdominal CT scans concluded a technical note written by a team of physicians from Johns Hopkins Medical and published in the March/April 2008 edition of the Journal of Computed Assisted Tomography. "It [Low-osmolar contrast media] is relatively non-absorbable and of low risk to the patient if aspirated," according to the technical note. (Source: Pharma Industry News From Medical News Today)

Novelty of treatment for the masses

FT.com - Drugs and Healthcare — Fri, 04 Jul 2008 02:00:00 +0100

Sixty years ago tomorrow Aneurin Bevan symbolically conveyed the keys to the National Health Service to what is now Trafford General Hospital and declared it open. It... (Source: FT.com - Drugs and Healthcare)

Gps angry at cartel accusation

FT.com - Drugs and Healthcare — Fri, 04 Jul 2008 02:00:00 +0100

A drive to turn patients' right to choose their GP into a reality was launched yesterday by health ministers, triggering a fresh clash with the British Medical... (Source: FT.com - Drugs and Healthcare)

Shire pays out £260m for jerini

FT.com - Drugs and Healthcare — Fri, 04 Jul 2008 02:00:00 +0100

The FTSE 100 specialist pharmaceuticals company has widened its footprint in human genetic therapies with the acquisition of the German biotechnology group (Source: FT.com - Drugs and Healthcare)

Software firm focuses on not-so-blind dates

Investor's Business Daily: HEALTH — Fri, 04 Jul 2008 00:32:46 +0100

Think of Ideapoint 19 an online matchmaker bringing biotech inventors and biopharma companies together. In one corner, toiling away in academic... (Source: Investor's Business Daily: HEALTH)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Bad news for competitor turns into good news for celgene

Investor's Business Daily: HEALTH — Fri, 04 Jul 2008 00:32:46 +0100

Celgene's stock movement last week had a familiar ring to it, only this time with a different twist. (Source: Investor's Business Daily: HEALTH)

Orbid corporation: orbid corporation and datalase settle patent infringement case

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 22:05:00 +0100

SAN FRANCISCO, CA (MARKET WIRE) ORBID Corporation, Inc., a leading provider of fingerprint/Unique Identity (UID) solutions for cost-effectively and securely guaranteeing the authenticity and integrity of products, today announced they have reached a settlement agreement with DataLase, Ltd. related to patents on ORBID's 2DMI technology. As a result, ORBID is withdrawing its case against DataLase, while continuing to pursue the case against FractureCode, a division of Filtrona PLC. (Source: Market Wire - Pharmaceuticals and Biotech)

Xechem international inc.: xechem international announces conference call to address information update

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 20:34:00 +0100

EDISON, NJ (MARKET WIRE) Xechem International (PINKSHEETS: XKEM) today announced today that it will be holding a conference call to update shareholders and other interested persons on its business operations and financial status. Details for the call are: (Source: Market Wire - Pharmaceuticals and Biotech)

Bioheart, inc., board appoints howard j. leonhardt chief executive officer

HSMN NewsFeed — Thu, 03 Jul 2008 20:21:36 +0100

SUNRISE, Fla., July 3 (HSMN NewsFeed) -- Bioheart, Inc., (Nasdaq: BHRT ) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today anno... Regenerative Medicine, Cardiology, PersonnelBioheart (Source: HSMN NewsFeed)

Free vaccine inc.: givevaccines.org creates quiz web site to donate life-saving vaccines to impoverished children around the world through the gavi alliance

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 20:06:00 +0100

ORANGE, CA (MARKET WIRE) Free Vaccine Inc., a non-profit organization dedicated to raising awareness about vaccine-preventable diseases and empowering individuals to be a part of the solution, has launched www.GiveVaccines.org. The site features a fast-paced vocabulary quiz focusing on word roots, English words and medical terminology. For every correct answer, GiveVaccines.org will donate .01 milliliter (ml) of life-saving vaccine to the GAVI Alliance vaccine program. (Source: Market Wire - Pharmaceuticals and Biotech)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Booktalk: dr. eamonn quigley reveals crucial health benefits of taking probiotics

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 19:48:00 +0100

LOS ANGELES, CA (MARKET WIRE) According to gastroenterologist and President of World Gastroenterology Organization Dr. Eamonn Quigley, your overall health depends on the healthy functioning of your digestive system. Your digestive system not only pulls nutrients from food to nourish the body, but it participates in protecting it from disease. The bacteria that populate the digestive tract play a critical role in both of these functions. (Source: Market Wire - Pharmaceuticals and Biotech)

Medivation to host conference call at 5 p.m. edt monday to discuss top-line phase 2 study results in huntington's disease

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 19:45:07 +0100

SAN FRANCISCO, July 03, 2008 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results from its randomized, double-blind, placebo-controlled Phase... (Source: Drugs.com - Clinical Trials)

Catalyst screen patients for clinical trial

bizjournals.com Health Care:Pharmaceuticals headlines — Thu, 03 Jul 2008 19:06:51 +0100

Catalyst Pharmaceutical Partners said it has begun enrollment for its U.S. Phase II clinical trial of a treatment for patients addicted to methamphetamine. (CPRX) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Wyeth pharmaceuticals-progenics drug relistor ok'd in europe

bizjournals.com Health Care:Pharmaceuticals headlines — Thu, 03 Jul 2008 18:56:28 +0100

Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc. received marketing approval from the European Commission Thursday for Relistor, a treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care. (WYE) (PGNX) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

The best medicine for the nhs at 60

FT.com - Drugs and Healthcare — Thu, 03 Jul 2008 18:19:00 +0100

As spending growth slows, the health service in all four parts of the UK needs to demonstrate through reform and innovation that it can deliver improvements (Source: FT.com - Drugs and Healthcare)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Medicago inc.: medicago receives contribution from nrc-irap for seasonal flu vaccine program

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 16:46:00 +0100

QUEBEC CITY, QUEBEC (MARKET WIRE) Medicago Inc. (TSX VENTURE: MDG) today announced it has been awarded a non-refundable contribution of up to $279,700 from Canada's National Research Council Industrial Research Assistance Program ("NRC-IRAP") to support the development of the Company's seasonal influenza Virus-Like Particles (VLP) vaccine program. Medicago is developing a seasonal vaccine based on its proprietary VLP manufacturing technology, which has the potential to offer speed and cost advantages over competitive technologies. (Source: Market Wire - Pharmaceuticals and Biotech)

Perkinelmer opens center to research stem cells from umbilical cords

bizjournals.com Health Care:Pharmaceuticals headlines — Thu, 03 Jul 2008 16:09:01 +0100

PerkinElmer Inc. has created a center dedicated to researching the potential uses of stem cells taken from umbilical cords, the company said Thursday. (PKI) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Shire to buy jerini of germany for $518m

bizjournals.com Health Care:Pharmaceuticals headlines — Thu, 03 Jul 2008 15:39:02 +0100

Shire Ltd. entered into a deal Thursday to buy Jerini AG, a German biotechnology company, for $518 million. (SHPGY) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Phase iii ariser study with rencarex: patient recruitment successfully completed

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 14:45:16 +0100

MUNICH, Germany, July 3,2008- Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) today announced that it has successfully completed patient recruitment in the Phase III ARISER trial with... (Source: Drugs.com - Clinical Trials)

Studies of adolor-glaxosmithkline's entereg can resume

bizjournals.com Health Care:Pharmaceuticals headlines — Thu, 03 Jul 2008 14:24:21 +0100

The Food and Drug Administration said Thursday that clinical studies of Entereg as a treatment for chronic bowel dysfunction such as constipation related to use of opioid painkillers can resume. (ADLR) (GSK) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Blood vessel inhibitor shows promise against metastatic thyroid cancer researchers also find evidence tying a genetic mutation to clinical outcome

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 13:55:06 +0100

HOUSTON, July 2, 2008 - Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by... (Source: Drugs.com - Clinical Trials)

Evotec's evt 101 well tolerated in four week higher repeat dose safety study

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 13:45:03 +0100

HAMBURG, Germany, July 3, 2008 -Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA receptors... (Source: Drugs.com - Clinical Trials)

Cutting edge information: oncology market to grow to $85 billion by 2013, according to new therapeutic study by cutting edge information

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 13:38:00 +0100

RESEARCH TRIANGLE PARK, NC (MARKET WIRE) The oncology market will grow from $57 billion in 2007 to more than $85 billion in 2013, according to a new report by Cutting Edge Information. (Source: Market Wire - Pharmaceuticals and Biotech)

Resolvyx scientific advisors publish first in-vivo data showing resolvins suppress il-23 and il-17, key mediators of inflammatory disease

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 13:30:30 +0100

BEDFORD, Mass.--(BUSINESS WIRE)--Jul 3, 2008 - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the... (Source: Drugs.com - Clinical Trials)

Vavelta: phase ii data presented at face and commercial sales commenced

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 13:25:20 +0100

CAMBRIDGE, England, July 3, 2008-Intercytex Group plc (LSE: ICX) the leading developer of regenerative medicine products to restore skin and hair, today announces that positive 6 month follow-up data from two Phase II trials of VAVELTA, its cell... (Source: Drugs.com - Clinical Trials)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Edap expands ablatherm-hifu business in germany

Medical News (via PRIMEZONE) — Thu, 03 Jul 2008 13:00:00 +0100

LYON, France, July 3, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today it has entered into two new revenue per procedure (RPP) contracts in Germany with St. Barbara Hospital in Gladbeck and the Urological Clinic of the University of Heidelberg. (Source: Medical News (via PRIMEZONE))

New research indicates that adrenal nodules not being adequately evaluated

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 12:50:03 +0100

BOSTON--(BUSINESS WIRE)--Jul 2, 2008 - A new study published in Endocrine Practice found that a substantial percentage of patients with nodules, or growths, in their adrenal glands were not being properly evaluated by physicians. Adrenal glands are... (Source: Drugs.com - Clinical Trials)

P&g quits collaboration with aryx therapeutics

bizjournals.com Health Care:Pharmaceuticals headlines — Thu, 03 Jul 2008 12:48:33 +0100

Aryx Therapeutics Inc. said Wednesday that Procter & Gamble Pharmaceuticals Inc. is exercising an option to end its collaboration with the company on development of a drug for chronic constipation and indigestion. (PG) (ARYX) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Aryx therapeutics, inc. announces successful results of qt study on ati-7505

Drugs.com - Clinical Trials — Thu, 03 Jul 2008 12:40:58 +0100

FREMONT, Calif.--(BUSINESS WIRE)--Jul 2, 2008 - ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of an important cardiac safety study on its prokinetic agent, ATI-7505. The overall results of a... (Source: Drugs.com - Clinical Trials)

Hls: hls continues to grow

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 11:00:00 +0100

PARSIPPANY, NJ (MARKET WIRE) HLS, the founding CommonHealth medical-education unit, today announced two promotions and four new hires. (Source: Market Wire - Pharmaceuticals and Biotech)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

The great drug debate

Forbes.com Healthcare News — Thu, 03 Jul 2008 10:13:51 +0100

An FDA meeting on diabetes provides a window into controversies that are shaking the drug industry. (Source: Forbes.com Healthcare News)

Ms drug development agreement based on wehi's medicinal chemistry

Pharma Industry News From Medical News Today — Thu, 03 Jul 2008 10:00:00 +0100

Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany- based pharmaceutical company, Merck Serono. Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions. (Source: Pharma Industry News From Medical News Today)

17.06.08: bayer group: names figures facts

Bayer IR Newsfeed: New on this site — Thu, 03 Jul 2008 08:29:59 +0100

Bayer Group: Names Figures FactsNew: Names Figures Facts 2008 / 2009Link to websiteAll changes (Source: Bayer IR Newsfeed: New on this site)

It benefits from smart shopping

Investor's Business Daily: HEALTH — Thu, 03 Jul 2008 08:00:00 +0100

Another day, another acquisition for Almost Family. Or so it seems. Almost Family, a provider of in-home nursing and therapeutic care, has been on... (Source: Investor's Business Daily: HEALTH)

Teva receives first u.s. approval for generic risperdal(r) tablets; commences commercial launch

Pharma Industry News From Medical News Today — Thu, 03 Jul 2008 08:00:00 +0100

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Janssen's antipsychotic agent Risperdal® (Risperidone) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Shipment of these products has commenced. (Source: Pharma Industry News From Medical News Today)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Canadian business groups applaud bold, competitive vision set out by competition policy review panel

Pharma Industry News From Medical News Today — Thu, 03 Jul 2008 07:00:00 +0100

A broad coalition of Canadian business groups welcomes the bold vision and ambitious scope of the final report of the Competition Policy Review Panel and calls on the federal government to secure the economic future of all Canadians by acting quickly on the report's recommendations. (Source: Pharma Industry News From Medical News Today)

Skyepharma plc: skyepharma plc announces research update

Market Wire - Pharmaceuticals and Biotech — Thu, 03 Jul 2008 06:00:00 +0100

LONDON (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech)

Professor defends research on fda

WSJ.com: Health — Thu, 03 Jul 2008 04:00:00 +0100

A Harvard University professor defended research suggesting the FDA was making overly hasty approval decisions on medicines, an analysis the agency has criticized as mistaken. (Source: WSJ.com: Health)

Unitedhealth lowers outlook, settles lawsuits

Medscape Business of Medicine Headlines — Thu, 03 Jul 2008 03:19:46 +0100

UnitedHealth Group slashed its full-year earnings outlook on Wednesday because of tough competition in the health benefits business and said it would pay more than $900 million to settle lawsuits related to past stock options practices. Reuters Health Information (Source: Medscape Business of Medicine Headlines)

Unitedhealth settles suits

WSJ.com: Health — Thu, 03 Jul 2008 03:13:00 +0100

UnitedHealth agreed to pay more than $900 million to resolve shareholder lawsuits stemming from an options-backdating case. (Source: WSJ.com: Health)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Upgrade of diabetes-drug standards urged

WSJ.com: Health — Thu, 03 Jul 2008 03:08:00 +0100

An FDA panel of outside medical experts said the agency should raise standards for approving diabetes drugs, a move that could affect the $5 billion-plus diabetes drug market in the U.S. (Source: WSJ.com: Health)

Nhs celebrations clouded by threat to founding principles

FT.com - Drugs and Healthcare — Thu, 03 Jul 2008 02:00:00 +0100

As Britain's tax-funded National Health Service prepares to celebrate its 60th birthday on Saturday, an overwhelming majority of those who use the system fear its core... (Source: FT.com - Drugs and Healthcare)

Ashley house up despite sales fall

FT.com - Drugs and Healthcare — Thu, 03 Jul 2008 02:00:00 +0100

Ashley House, which manages the construction of medical centres and doctors' surgeries for the National Health Service, increased annual profits in spite of a fall in... (Source: FT.com - Drugs and Healthcare)

Legal decision boosts astrazeneca

FT.com - Drugs and Healthcare — Thu, 03 Jul 2008 02:00:00 +0100

Shares in AstraZeneca rose nearly 5 per cent on Wednesday after a US legal ruling pushed back the likely launch of a generic version of Seroquel, its blockbuster schizophrenia medicine, until 2011 (Source: FT.com - Drugs and Healthcare)